@article{JGO27017,
author = {Ashwin Shinde and Vivek Verma and Richard Li and Scott Glaser and Mustafa Raoof and Susanne G. Warner and Vincent Chung and Gagandeep Singh and Yi-Jen Chen and Karyn A. Goodman and Arya Amini},
title = {The role of sequential radiation following adjuvant chemotherapy in resected pancreatic cancer},
journal = {Journal of Gastrointestinal Oncology},
volume = {10},
number = {3},
year = {2019},
keywords = {},
abstract = {Background: Optimal adjuvant therapy for resectable pancreatic cancer remains controversial. The Radiation Therapy Oncology Group (RTOG) 0848 is evaluating adjuvant chemotherapy (CT) with or without sequential chemoradiation in the absence of disease progression. In the absence of completed RTOG 0848 data, we addressed the question through a retrospective analysis.
Methods: The National Cancer Database was queried for non-metastatic, histologically-confirmed pancreatic carcinoma status post resection and adjuvant CT. Patients receiving neoadjuvant therapy were excluded. Multivariable logistic regression was performed to identify factors associated with receipt of sequential radiation therapy (RT) starting at least 4 months after CT, with generation of propensity scores. Log-rank analysis assessed univariate overall survival (OS), while multivariable Cox proportional hazards modeling examined multivariate OS. Six-month landmark analysis was performed to allow for completion of all planned adjuvant therapy.
Results: Of 15,661 patients, 14,167 (90.5%) underwent CT alone, and 1,494 (9.5%) received RT. Patients receiving RT had nodal disease and R+ resection more often (P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/27017}
}